Alabama warns doctors against prescribing unregulated research-grade peptides

Alabama’s medical regulator has moved to shut down a fast-growing loophole in wellness medicine: non-FDA-approved peptides sold online as “research-grade” products, then funneled to patients through prescribers who may treat consent forms as a shield. The state Board of Medical Examiners warned physicians and other licensed professionals not to prescribe, administer, dispense or recommend those substances, saying they are outside FDA oversight for safety, effectiveness and manufacturing standards.

The alert, issued in Montgomery on May 26, said doctors must obtain prescription drugs and ingredients only from properly permitted sources. It also drew a hard line on paper defenses: patient waivers or consent forms labeling a substance as research-grade do not erase a provider’s legal or professional responsibilities. For patients, that means a product marketed as a shortcut around regulation remains a risk even if a clinic asks them to sign a form before treatment.

The warning lands in a market where sellers often blur the line between laboratory materials and medicines. The FDA has already said bulk drug substances used in compounding may present significant safety risks, and it uses a category system for compounds that raise those concerns. In 2025 and 2026, federal warning letters targeted online sellers of peptide-related products marketed with “research only” disclaimers but presented in ways that suggested human use.

Those letters show how broad the problem has become. The FDA warned Pinnacle Professional Research dba Pinnacle Peptides on December 12, 2025. On March 31, 2026, it sent warning letters to Prime Sciences and Mile High Compounds LLC. In the Prime Sciences letter, the agency said injectable products can pose serious harm because they bypass some of the body’s defenses against toxins and microorganisms. In the Mile High Compounds case, the FDA said peptide-like products were unapproved new drugs.

Alabama had already signaled concern before this new alert. A July 18, 2024 declaratory ruling said some outlets were selling semaglutide salt forms and “research-grade powder” that were not approved by the FDA and had not been evaluated for safety. Now the warning is broader and sharper, aimed not just at sellers but at prescribers who may have normalized a regulatory gray zone.

That gray zone is drawing federal scrutiny as well. The FDA is set to convene an advisory panel in July 2026 to consider whether certain peptides should be allowed in compounding pharmacies. Until that debate is resolved, Alabama’s message is blunt: if a peptide is sold online as research-only, lacks FDA approval, or arrives with a waiver instead of real oversight, the danger has already been baked in.